Biotechnology policies

Workshop on Building an Efficient Bio-Based Economy Through Industrial Biotechnology - Agenda and Presentations

 

Agenda and Presentations

 

DAY 1 – Thursday 28 October 2010


Workshop Chair: Marvin DUNCAN, Chairman of the OECD Task Force on Industrial Biotechnology

Welcome and Introductory remarks

Ilya KLEBANOV, President's Plenipotentiary in the North-West Federal District (Russia)
Stanislav NAUMOV, States Secretary, Deputy Minister, Ministry of Trade and Industry Russian Federation
Dmitry FILATOV, Advisor, Department of International Integration, Russian Federation Ministry of Education and Science, Russia
Vyacheslav TRUBNIKOV, Chairman of the Supervisory Board, Russian BioIndustry Association (Russia)
Marvin DUNCAN, Chairman of the OECD Task Force on Industrial Biotechnology

 

Keynote Addresses

Stanislav A. NAUMOV, States Secretary, Deputy Minister, Ministry of Trade and Industry Russian Federation
Robert WELLS, Head of the Biotechnology Unit, Science and Technology Policy Division, OECD
“Bioeconomy in the OECD Countries: Current State and Outlook”

SESSION I – Governmental Policy for the Development of Bio-Based Economy – Sharing Experience

Objectives:  i) To get an overview of current approaches used by the BRIC governments for creating a policy environment enabling industrial biotechnology and ii) to map successful policy approaches specific to the BRIC countries and key failures.

 

Facilitator for Session 1Monika SORMANN, Policy Advisor, Department of Economy, Science and Innovation, Ministry of Flanders, Belgium


Presentations on National Supportive Policies for Industrial Biotechnology

Vladimir POPOV, Director, Bach Institute of Biochemistry, Russian Federation  
Eduardo GIACOMAZZI, Head, Brazilian Biotech Association, Brazil
Christian PATTERMAN, Land Nord-Rhein Westphalia Counsellor, Member of the  BioEconomy Council of the German Government, Germany

 

Roundtable Discussion 
Questions to be addressed:

  • What are the main drivers for governments in supporting IB? What are the main policy priorities that have been set and what approaches have been used to support industrial biotechnology across its whole innovation cycle?
  • What is the current (or expected) impact of such policies on the economy?
  • How do we ensure the coherence and co-ordination between national and regional policies to support the development of IB and thus the economic development through IB? Are there any success stories? 
  • What are the most successful policy approaches for setting up national IB infrastructures? What are the main challenges faced?
  • What are the most efficient approaches that might be applied to co-ordinate policy development amongst various ministries and agencies concerned?
  • How do governments facilitate (or can facilitate) the integration of national IB networks into international IB consortia and networks? 

 

SESSION I – Governmental Policy for the Development of Bio-Based Economy – Sharing Experience (continued)


Roundtable Discussion (continued)

Synthesis of Main Discussion Points
Monika SORMANN, Policy Advisor, Department of Economy, Science and Innovation, Ministry of Flanders, Belgium

 

SESSION II – Business Environment for the Bio-Based Economy: Toward Sustainability

 

Objective: To identify the new industrial biotechnology structural trends and to map the current and emerging business models in this sector.

 

Facilitator for Session II:  Martin AUSTIN, Managing Director, TransformRx, Basel, Switzerland

Presentations on Business Trends in Industrial Biotechnology and its organisation in the BRIC countries

 

Xiaguang GAO, Assistant Director and Professor, Institute of Biophysics, Chinese Academy of Sciences, China
Raif VASILOF, President, Russian Biotechnology Society, Russian Federation

Manfred KIRCHER, Chairman of CLIB2021, Germany

Roundtable Discussion
Questions to be addressed:

  • What are the most attractive IB opportunities for the BRIC countries? What are the main drivers to capture the opportunities and how they are perceived by the business environment? 
  • What initiatives (e.g. business development, co-ordination, fund raising, interaction with academia, etc.) has the IB private sector developed and implemented place to capture the opportunities?
  • What initiatives were the most successful? What kinds of challenges have been faced while developing and implementing initiatives and how these have been overcome?
  • What are the success stories in creating necessary infrastructure and conditions for fast commercialisation of the industrial biotechnology products/technologies?
  • What challenges are faced by the private sector in industrial biotechnology while integrating international infrastructure and market? 
  • What kind of policy support world the IB private sector would need to bring the sector to maturity and higher efficiency?


Synthesis of Main Discussion Points
Martin AUSTIN
, Managing Director, TransformRx, Basel, Switzerland  

 

Synthesis of the Day – Summary of Conclusions

Marvin DUNCAN, Chairman of the OECD Task Force on Industrial Biotechnology

 

DAY 2 – Friday 29 October 2010

Session III- Building Efficient Cooperation in Globalising Bio-Based Economy

Objectives:  To formulate practical recommendations on how to build a more efficient bio-based economy in the BRIC countries while aligning the interests of all actors involved.

 

Facilitator for Session III:  Alexander BARSTEV, Policy Analyst, Science and Technology Policy Division, OECD 

 

Cooperation with the BRIC countries to build a more efficient bio-based economy

John CLAXTON, Deputy Head of Unit, Biotechnologies, DG Research, EU.
Christian PATTERMAN, Land Nord-Rhein Westphalia Counsellor, Member of the  BioEconomy Council of the German Government, Germany.

Roundtable Discussion
Questions to be addressed:

  • Formulation of practical recommendations on efficient coordination amongst ministries and national agencies to efficiently develop and implement IB supportive policies;
  • Formulation of practical recommendations on a more efficient coordination and cooperation amongst all actors of the IB innovation cycle;
  • Formulation of practical recommendations on a more efficient commercialisation of IB products and services;
  • Formulation of practical recommendations on mechanisms for multilateral cooperation in IB S&T such as the involvement of national networks into the activities of established international consortia (ERA-NET, FP7), etc.

Next Steps
Alexander Barstev, Policy Analyst, Science and Technology Policy Division, OECD 

 

Closing of the Workshop
Workshop Chair: Marvin DUNCAN, Chairman of the OECD Task Force on Industrial Biotechnology

 

 

 

Countries list

  • Afghanistan
  • Albania
  • Algeria
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Brazil
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China (People’s Republic of)
  • Chinese Taipei
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Croatia
  • Cuba
  • Cyprus
  • Czech Republic
  • Côte d'Ivoire
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • Dominican Republic
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • European Union
  • Faeroe Islands
  • Fiji
  • Finland
  • Former Yugoslav Republic of Macedonia (FYROM)
  • France
  • French Guiana
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iraq
  • Ireland
  • Islamic Republic of Iran
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jersey
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kuwait
  • Kyrgyzstan
  • Lao People's Democratic Republic
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Libya
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macao (China)
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia (Federated States of)
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestinian Administered Areas
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Romania
  • Russian Federation
  • Rwanda
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Vincent and the Grenadines
  • Samoa
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Serbia and Montenegro (pre-June 2006)
  • Seychelles
  • Sierra Leone
  • Singapore
  • Slovak Republic
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Sudan
  • Spain
  • Sri Lanka
  • Sudan
  • Suriname
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • Tajikistan
  • Tanzania
  • Thailand
  • Timor-Leste
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Virgin Islands
  • Uruguay
  • Uzbekistan
  • Vanuatu
  • Venezuela
  • Vietnam
  • Virgin Islands (UK)
  • Wallis and Futuna Islands
  • Western Sahara
  • Yemen
  • Zambia
  • Zimbabwe